LAS
NTLA icon

Lloyd Advisory Services’s Intellia Therapeutics NTLA Stock Holding History

Lloyd Advisory Services’s Portfolio NTLA Stock Details NTLA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Hold
0
– – – 857
2022
Q2 		– Sell
-45
Closed -$3K – 392
2022
Q1 		$3K Buy
+45
New +$3.81K ﹤0.01% 484

Other funds holding NTLA

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
RP
Regeneron Pharmaceuticals Tarrytown, New York $177M AUM 9.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Lloyd Advisory Services's NTLA Position: Q1 2026 in Review

Lloyd Advisory Services held its Intellia Therapeutics (NTLA) position steady in Q1 2026 at 0 shares worth $2. The position accounts for ﹤0.01% of the portfolio, ranked #857.

Lloyd Advisory Services first reported a position in NTLA in Q1 2022 and has held it in 1 quarter since. The position peaked at $3K in Q1 2022. 304 funds tracked by Wall St. Rank hold NTLA as of Q1 2026.

  • Lloyd Advisory Services held 0 shares of Intellia Therapeutics worth $2 as of Q1 2026.
  • Lloyd Advisory Services left its Intellia Therapeutics share count unchanged in Q1 2026.
  • Intellia Therapeutics made up ﹤0.01% of Lloyd Advisory Services's portfolio in Q1 2026, its #857 holding.
  • Lloyd Advisory Services first reported a position in Intellia Therapeutics in Q1 2022 and has held it in 1 quarter since.
  • Lloyd Advisory Services's Intellia Therapeutics position peaked at $3K in Q1 2022.
  • 304 funds tracked by Wall St. Rank held Intellia Therapeutics as of Q1 2026.

Based on Lloyd Advisory Services's 13F filing for Q1 2026, filed 13 May 2026.